22May 2023
EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveries

EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveries

Anaplastic lymphoma kinase (ALK) can be driven to oncogenic activity by different types of mutational events such as point-mutations, for example, F1174L in neuroblastoma, and gene fusions. EML4-ALK variants result from different breakpoints, generating different sizes and properties of fusions. The most common variants (Variants 1 and 3) form cellular compartments with distinct physical properties. A partial, probably misfolded beta-propeller domain in variant 1 confers solid-like properties to the compartments it forms, greater dependence on Hsp90 for protein stability and higher cell sensitivity to ALK tyrosine kinase inhibitors (TKIs). This article discusses the biology of EML4-ALK variants, their impact on treatment response, ALK-TKI drug resistance mechanisms and potential combination therapies.

  • #oncology

Like

Save

Share